550 non-injected doses in Calais, 670 in Gravelines and 160 in Boulogne-sur-Mer. Associated with rare cases of thrombosis, the AstraZeneca vaccine continues to arouse mistrust, especially in Hauts-de-France. Even forcing some centers to close their doors for lack of volunteers to be vaccinated, as was the case last weekend.
In Paris or Saint-Quentin-en-Yvelines, a similar finding, but with Moderna’s vaccine this time. Of the 6,700 meetings at the Stade de France vaccinodrome, almost the majority of Pfizer slots are filled, when there are still a hundred available with Moderna – while they use the same technology, by messenger RNA. “Astra and Moderna, it rhymes, so people confuse the two,” said Frédéric Adnet, head of the emergency department at Bobigny hospital, on BFMTV. “Moderna clearly has a popularity deficit, perhaps because it has been less used in France so far,” abounds Katy Bontinck, first deputy mayor of Saint-Denis.
97% of AstraZeneca doses used in Brittany
In Brittany, the situation is quite different. In the region, the doses find each time a taker. Thus, as of April 5, 97% of the doses of AstraZeneca received have been injected. Consecrating our territory as the one that most quickly administered its stock in France.
Can we say that the Breton is crazy about the AstraZeneca? That would be reductive. First, it can be seen that the curve of the doses administered took time to match that of the doses delivered. A gap which is partly explained by a sluggish start for AstraZeneca in the region, after the appearance of side effects, especially in nursing staff. What has cooled more than one.
On the other hand, the Brittany did not benefit from restocking with AstraZeneca the week of March 17. And the March 23 delivery brought only 800 new bottles. With almost constant stock since mid-March, the utilization rate could therefore only increase until the beginning of April with the appointments to be met.
65,000 new doses should be sent this week to medical offices and Breton pharmacies.
Pfizer doses, as soon as they arrive, as soon as they are used
Conversely, we can speak of a real attraction of the Bretons for the Pfizer vaccine. With 95% use on April 5, vaccination is done at a constant flow. The doses arrived are almost all used during the week.
An observation that is also found at the national level, so that the messenger RNA vaccine is described as a “blockbuster” in the corridors of the Ministry of Health. The distribution pattern of this vaccine – vaccinators who travel directly to nursing homes and the opening of large vaccination centers – could have helped speed up its injection. The negative image of the vaccine at the beginning, when the start was slowed down in nursing homes, has lived.
Moderna, “victim” of low deliveries
The situation of Moderna’s solution is special. Daily vaccinations have never really taken off: on April 5, there were barely 500 doses administered each day on average in Brittany. As a result, only 61% of the bottles delivered were consumed.
But this is largely the result of low deliveries. In two and a half months, only 50,000 doses were received.
“We are delivered in doses every two weeks, which requires us to manage more measured stocks, so as not to find ourselves struggling in the event of a production delay when it comes to administering the second doses” , explains the Directorate General of Health. Difficult, under these conditions, to quantify the reluctance or adhesion to the vaccine in the region.
A “new kid” should soon arrive: the first 550,000 doses of the vaccine from the Janssen / Johnson & Johnson laboratory are scheduled in France for April 20 and 27. It is difficult, for the moment, to know how many will be sent to Brittany, part of this first delivery to be sent to overseas territories, the other to benefit “people in a very precarious situation”.
This product has the great advantage of not require only one injection. It should be administered in pharmacies and in doctors’ offices.
Support a professional editorial staff at the service of Brittany and the Bretons: subscribe from € 1 per month.